Stem Cell Therapy at Stem Cell Institute on PBS-TV Dallas-Fort Worth this Sunday! PBS KERA TV-13

Brenda Watson Show. KERA
PBS TV (KERA 13) in Dallas-Fort Worth – Go inside our clinic and lab in Panama, and watch interviews with 3 patients. The other episode follows a knee patient through the treatment process at Dr. RIordan’s orthopedic stem cell clinic in Southlake, Texas. Sunday, January 29th from 12pm – 1pm.

Stem Cells I

Riordan-McKenna Institute – Stem Cell Therapy for Orthopedics

Take a journey with marathon runner and knee patient Jim Morella as he undergoes a stem cell augmented arthroscopic knee procedure. Peer inside the operating room as Dr. McKenna harvests stem cells from Jim’s bone marrow, prepares them, and injects them into his knee. Tag along with Brenda as she interviews Jim at home following his recovery.

Dr. McKenna discusses Jim’s case with Brenda and explains why stem cell injections alone are not necessarily the best solution to knee problems, including Jim’s. He also touches upon the FDA’s current role regarding regulations.

Dr. Riordan talks about how the proprietary amniotic membrane tissue product used by RMI can enhance bone marrow stem cell therapy and the safety aspects of such treatments.

Dr. McKenna Stem Cell Augmented Surgery 3

Stem Cells II

Stem Cell Institute in Panama: Spinal Cord Injury, Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and More…

Brenda Watson takes you inside the Stem Cell Institute and Medistem Labs in Panama. If you have ever wondered what stem cell therapy is like in Panama, this show is for you.

See inside the laboratory and clinic as Brenda follows three patients through the treatment and recovery process: Sam Harrell (MS), Juan Jose Ballareno (Spinal Cord Injury) and Todd Rinehart (RA).

Meet the team as she interviews key players:

Neil Riordan, PhD, Founder and Chief Scientist of Medistem Labs, explains how the Panamanian government regulates stem cells in Panama. He discusses how HUCT-MSCs work on RA before delving into the subject of clinical trials in Panama and the USA.

Medical director, Jorge Paz Rodriquez, MD discusses how HUCT-MSCs work and why they can be transplanted without immune system rejection.

Rodolfo Fernandez, Medistem Panama Laboratory Director talks about tissue selection and processing.

Applied Stem Cell Therapy Expert, Neil Riordan, PhD, Authors “Cell Therapy for Liver Failure: A New Horizon” in Contemporary Liver Transplantation Medical Reference

DALLAS-FORT WORTH, TEXAS (PRWEB) NOVEMBER 08, 2016 (Original Press Release on PRWeb)

Picture of Neil Riordan, PhD

Neil Riordan, PhD

A new chapter by renowned applied stem cell therapy expert, Neil Riordan, PhD of the Riordan-McKenna Institute in Southlake, Texas; Medistem Labs Panama, and the Stem Cell Institute in Panama City, Panama, entitled, “Cell Therapy for Liver Failure: A New Horizon” is now available in the printed and online medical reference, “Contemporary Liver Transplantation – The Successful Liver Transplant Program”.

Contemporary Liver Transplantation provides a comprehensive review of the most crucial and provocative aspects of liver transplantation. The reference covers all disciplines involved in a multidisciplinary liver transplant team; provides a valuable resource for surgeons, hepatologists, anesthesiologists, transplant coordinators and administrators, amongst others; addresses organizational issues that are vital to the good performance of transplant programs; and offers the first 360-degree analysis of liver transplantation.

Liver failure is the seventh largest cause of death in industrialized countries. It occurs as a result of a number of acute and chronic clinical inciting factors, including drug-/alcohol-induced hepatotoxicity, viral infections, vascular injury, autoimmune disease, or genetic predisposition. The only available cure, liver transplantation, is severely limited by a lack of donors and further complicated by the adverse effects of chronic immune suppression.

In his chapter on stem cell therapy for liver failure, Dr. Riordan examines pre-clinical data and analyzes published clinical trials to identify promising sources of autologous stem cells to treat liver failure including: bone marrow mesenchymal stem cells (BM-MSC), adipose tissue MSC (AT-MSC), and bone marrow mononuclear cells (BMMC) including their purified forms. In addition, he delves into allogeneic stem cells such as those harvested from umbilical cords after normal, healthy births.

“Many liver failure patients contact our clinics in Panama and Texas asking if there is anything we can do for them. Unfortunately, we have to tell them that we cannot treat liver failure. Even though some clinical trials have shown signals of efficacy, which is encouraging, I don’t think sufficient rationale exists to treat liver failure patients with the types of stem cells I’ve studied at present,” stated Dr. Riordan.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis.

Additionally, RMI augments orthopedic surgeries with BMAC and amniotic tissue allograft to promote better post-surgical outcomes and uses amniotic membranes as part of a complete wound care treatment regimen.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. Amniotic tissue allograft is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*Amniotic tissue is donated after normal healthy births.

Riordan-McKenna Institute Website: http://www.rmiclinic.com

Riordan-McKenna Institute
801 E. Southlake Blvd.
Southlake, Texas 76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor *human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2017, Translation Biosciences plans to expand its clinical trial portfolio to include heart disease and cerebral palsy.
*umbilical cord tissue is donated after normal, healthy births

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Website: http://www.medistempanama.com

About Contemporary Liver Transplantation

Edited by Cataldo Doria, Contemporary Liver Transplantation provides a comprehensive review of the most crucial and provocative aspects of liver transplantation. It represents a unique source of information and guidance for the current generation of transplant surgeons that evolved from being pure clinicians into savvy administrators knowledgeable in every regulatory aspect governing transplantation.

The book contains 35 chapters covering every single aspect of the surgical operation in the donors as well as the recipients of liver transplants. The pre-operative work-up, as well as the post-operative immunosuppression management and the treatment of recurrent diseases are addressed in detail. Single chapters are dedicated to controversial issues like transplantation in patients diagnosed with NASH, transplantation for patients diagnosed with HCC beyond Milan criteria and usage of HIV positive donors. Dedicated chapters on HCV, HCC, FHF and NASH will make this book a unique resource for any health care provider part of the multidisciplinary liver transplant team.

The book goes beyond the analysis of the formal medical and surgical aspects of liver transplantation and introduces deep knowledge on key aspects of contemporary transplant programs, such as: physical rehabilitation, palliative care, pregnancy, the multiple requirements of regulatory agencies ruling transplantation, quality measurements for transplant programs, finance and liability.

The book is organized in 9 sections focusing on each key aspect of liver transplantation. Contemporary Liver Transplantation addresses the need and the questions of the multidisciplinary group involved including surgeons, Hepatologists, anesthesiologists, infectious disease specialists, radiologists, transplant coordinators, financial specialists, epidemiologists and administrators.

Contemporary Liver Transplantation Online: http://www.springer.com/us/book/9783319072081

Neil Riordan, PhD discusses stem cell therapy on Larry North’s “Better you Show” – CBS KRLD 1080am

Picture of Larry North

Larry North

KRLD 1080

Larry North has been helping people become healthy for over 25 years. He’s done this with three best-selling books, seminars, and gyms. These people were no different than you. The only difference is that they chose to make a change in their life. Now it’s your turn. Don’t put it off any longer. Let Larry help you become an even better you. Here’s Larry North.

Larry: Hey everyone. We had a cold front. It went from 105 degrees down to 97. It was really like a cool breeze for everyone in North Texas. This is the Better You show. I’m just thrilled! I’m always seeking to help you in my quest to deliver the best experts, the best guests, the best technology, the best medical advice that you could possibly get; be it exercise or nutrition, and of course your health. My guest is Dr. Neil Riordan, chairman of MedStem out of Panama. There’s so much to talk about. He’s published dozens and dozens of scientific articles, [and] internally peer reviewed journals. He’s just a cutting edge expert when it comes to stem cells. In fact, he and his colleagues have published articles together on MS, spinal cord injuries, heart failure, arthritis, autism. He’s also CEO of Riordan-McKenna Institute right here in Southlake. So he’s local, but he’s actually more international that he is local. Just happens to be close by, consults with numerous universities, and I consider him a friend. You flew in from Wichita, which is where you’re from, right?

Image of Neil Riordan, PA, PhD

Neil Riordan, PA, PhD

NR: Yeah, that’s my hometown. We were doing a fund raiser for a young man who has Duchenne’s muscular dystrophy, and originally we started treating him in Panama using stem cells from umbilical cords, and he responded very well, and he responds each time he gets treated, but we have to keep treating him. It’s a very long-term treatment. He has to get new cells every 4-6 months. He is the first person in the US to get umbilical cord stem cells for any indication, and we’re under the FDA. They’ve given us an investigational new drug, compassionate use, because he was treated seven times out of the country, but they gave us the green light for him to get treated in the country. He’s been treated now three years, every four months now, and when he gets those stem cells his breathing goes up, everything improves. In fact, now, eight years later since his first treatment, he’s in better health now than he was at 22, and he’s about 30 and a half.

Larry: I’ve been around you long enough and I’ve heard these types of stories, I really hope we can inspire a lot of our listeners. I’d like to start from the beginning. Your father was really kind of a holistic pioneer when it came to better health, was he not?

NR: Absolutely. My father and later myself, we did a lot of work on cancer therapy, and what we worked most on was intravenous vitamin C for cancer treatment, decades ago, back when that was really quackery. Now we have universities like Thomas Jefferson starting their third clinical trial using intravenous vitamin C for cancer patients, university of Iowa, even Johns Hopkins has started a study. Some of these ideas take time to catch on, but they’re really catching on now.

Larry: What was it like growing up with a father so cutting edge, so way ahead of his time?

NR: I think in retrospect now I realize how brave he was in doing the things he was doing. As my brother says, you can recognize a pioneer by the arrows in his back. He certainly had a few, but I think his legacy is that those arrows were unwarranted, and now you have major universities carrying on the research. The quality of life of cancer patients when they get intravenous vitamin C has improved. It’s been proven. More and more literature comes out, and he’s being vindicated.

Larry: What I’ve found, and this is why I’m so excited to have you, what I’ve found is that I know just enough about stem cells to really be dangerous when I try to educate people, and I don’t. Most people really have no clue. They’ve heard of stem cells. They think they know a little bit about it, but they’re really not sure. They’ll just be inquisitive. Where did all the stem cell research start?

NR: It actually started with one of our other research projects alongside the vitamin C research at the Riordan Clinic in Wichita, where we were looking at host non-toxic therapies for cancer. One of them…, there are cells in your body called dendritic cells. They are commanders of the immune system. They tell the immune system what to do, and in cancer patients they’re being blocked. One way to overcome that blockade to the immune system is by enhancing these dendritic cells and harvesting white blood cells to convert to dendritic cells. That was late 80s, and I left in the 90s to start my own clinic to actually make dendritic cells, to make cancer-therapeutic vaccines for cancer patients. I was in the Riordan Clinic for fourteen years, working on intravenous vitamin C and dendritic cell vaccines.

Larry: Interesting. What are the most common types of stem cells people have available to them today? I want to talk about that, and also, why umbilical? From what I’ve read, if you want stem cells that’s where you want to go, but I understand there are other options. You were able to treat this young man locally, but most people have to go out of the country. What were the early stages of stem cell options for people and where has it evolved to?

NR: First I want to exclude embryonic and fetal stem cells, which are subject to a lot of debate–religious and ethical–and we want to exclude that because that’s not even part of our conversation. It’s from an ethical and scientific standpoint that we’ve never utilized or even studied embryonic or fetal stem cells. We only use what’s classified as adult stem cells, and what’s included in that, is after a full-term healthy birth, we call those post-natal or adult stem cells. Once a healthy, normal life has begun on until your demise, those are all considered adult stem cells, and we can separate those into two major categories: one is blood-forming stem cells that are formed in your bone marrow, and those are called hematopoetic stem cells or blood-forming cells because that’s what they do. There’s a lot of confusion these days about those cells being used to treat cancer or MS, but those cells don’t really treat anything. When you hear about a cancer patient being treated with stem cells, they’re actually being treated with chemotherapy and/or radiation, in the hope that they get a high enough dose to kill the cancer, but it also kills your bone marrow’s ability to produce blood cells, so you die of an infection or you die of bleeding or something like that. The stem cells in that world are a rescue, not a treatment. Your stem cells are gone. They’ve all been obliterated, so you need new stem cells and start making all these blood products again. The world we’re in are repair stem cells -the repair stem cells are found throughout your body called MSCs. We use the term MSC for mesenchymal stem cells. We have them throughout our body and as we age, they become fewer in number, and as we age they lose their ability to fix things. They become less robust. So you have them in your fat, your bone marrow, every organ in your body. The healthiest, most robust stem cells from a non-dangerous, non-controversial source are from the umbilical cord. If we look at the potency of umbilical cord MSCs compared to mine, I’m 57 years old, my cells are going to divide once every 50-60 hours, whereas the umbilical cord cells divide every 24 hours, which doesn’t sound like a lot, until you look at the numbers. One cell after 30 days you’re going to have a billion cells from one if they divide every 24 hours. If you look at my cells in a lab, I’ll have a pitiful 2-300 cells after that period of time. It’s not just the cells, but it’s also what the cells secrete, molecules that stimulate regeneration. Our cells because we’re over the age of 50, they do not produce as many of those factors that stimulate regeneration, they’re also less robust their capacity to modulate the immune system and decrease inflammation. We all know that inflammation is the real key to aging.

Larry: You’ve touched on a lot of things. You are so brilliant and so smart. You’re a scientist. One of the great things about having you, is that this is the future of medicine, and being able to explain to people how they work. I want more stories from people who are actually, truly changing their lives as the result of stem cells, but I also want to talk to you about the confusions. I’ve had some friends who have gone to Houston and had some body fat taken out of their body, processed, and what are the benefits of that vs. umbilical? We’ll come back and talk about that. [Commercial break] We’re talking about the umbilical stem cells. Let’s say someone lives in Dallas. How would they know if they’re a candidate for stem cells?

NR: Typically we would want them to go to our website, and we’d want them to read all about what we do what we don’t do there. [www.cellmedicine.com]

Larry: So let’s say they go to the site, and one of my sponsors here is BioMedical and they’re about hormone optimization, and I love that your clinic actually does BioT. So if you’re thirty, and you test your testosterone levels and it’s high, let’s say above 800, they’d tell you you’re not a candidate for it. What tells you about who needs stem cells?

NR: We have a number of protocols. One of the things we do most of is we treat autoimmune diseases, and one of the indications we have is multiple sclerosis, rheumatoid arthritis and others. The cells are very good when you infuse them in the vein. They change the auto-immune environment in the body. If someone wants to explore it as a treatment option, they’d go to the site and read about what we do and fill out an application. We have six MDs that work at the Stem Cell Institute in Panama. They review every case and will call them and typically ask them for medical records.

Larry: I’ve been there, to Panama, visited and got to work with your medical professionals, and I found it an amazing experience because for me, it was orthopedic because of the fact that I was a body-builder back in the 70s and 80s and we did things back then we probably shouldn’t have done. We sort of didn’t know any better. After being in several auto accidents, my neck, my back, my knee, and I have to tell you I had stem cells directly into the knee, and prior to meeting you I thought I was going to have to have surgery. In the month or so since we last saw each other, I don’t know what’s going on in my body but I’m feeling amazing. I want more of that! For me it was orthopedic. For others listening, you talked about inflammation, and stem cells are definitely able to help with that.

NR: Absolutely. They’re producers of the anti-inflammatory molecules in your body, the producers of your natural ibuprophen or naproxine. A lot of people, if they have a lot of arthritis, that’s another one of our protocols. Osteoarthritis, they don’t need to take those things anymore. We can inject right into the joint as well as do intravenous [injections]. The cells have this capacity to home to inflamed areas and respond to the situation to make the appropriate antibodies.

Larry: Let’s open up the phone lines. Let’s go to Said in Arlington:

Said: I am 60 years old and have been diagnosed with diabetes for six years. My A1C average is about 7-7.2. My question is, is there any research on diabetes and diabetic people? Will what you do help me?

NR: We don’t treat Type 2 diabetes in Panama, but there was a very good study done by the University of Miami, and they used bone marrow stem cells from the patient themselves, isolated the stem cells and pushed the stem cells into the pancreas, and if I remember correctly got a reduction in hemogloben A1C of 2.5 points was the mean for 20-some patients. I can post that study to my blog for you.

Said: Did that study proceed further?

NR: That was a one-time study and they followed the patients for a year. The procedure itself took one day, the bone marrow harvest, concentrating, and then the injection.

Said: What I have read, all these pharmaceutical companies are making money, tons of money, so naturally they don’t want anyone to promote to cure this disease. I’m sure there is a cure but no one wants to do the research.

Larry: Also, with Type 2, you do want to exercise, eat right, have your hormones in balance, take good care of yourself. That’s one of the best ways you can deal with your overall health and wellness, which you do control. Good luck to you. Neil, so, help me out here. Stem cells is a hot topic right now but you’ve been doing this for decades. You’ve devoted your life to it. I’ve seen and I’ve read on social media that locally, people are offering stem cells you can get locally. But really, without that special dispensation you have for one patient, what are people doing that are saying they can get it from a local clinic here.

NR: In our case at RMI in Southlake, we do stem cell therapy but we’re limited by FDA to using the patient’s own bone marrow. We also use amnion from afterbirth that has growth factors to make your bone marrow perform younger. We’ve got Dr. Wade McKenna, our board certified orthopedic surgeon. He does treatments using the patient’s own bone marrow in a relatively painless extraction procedure. He uses that in combination with amnion and with surgery. In his words, he likes to take big surgeries and make them small surgeries, and small surgeries and make them injections.

Larry: It’s a relatively new clinic but he’s busy, right?

NR: Yep, he’s done thousands of surgeries using bone marrow in Decatur and now he’s here, only for orthopedics, but we have another doctor there for overall wellness and optimization and hormone replacement therapies.

Larry: What led you to umbilical stem cells over other forms of stem cell treatment?

NR: It was mainly the science. One of the misconceptions is that the cells actually become new tissue. We have people come to us asking for new bladders and new body parts. These cells do not do that. These cells do home to places of inflammation in your body. That’s the sweet spot for these MSCs and they secrete substances that turn off these inflammations, and another sweet spot is autoimmune disease. If you look at what they secrete and their activity on the immune system and compare that to fat stem cells, you can get MSCs from your own fat, if you compare that, you have way more modulation potency from the umbilical cord than you do from your fat.

Larry: That’s quite significant.

NR: Basically you have to get this rock over a hill from an immune standpoint, and you can get halfway up the hill and it doesn’t do any good. If you want to get the rock over the hill, the best way to do it is with the best cells that produce the right molecules that stimulate your immune system to normalize.

Larry: The science agrees with you, there’s no question, but in the early stages, where did you go to get the cells in the first place?

NR: In Southlake, we have specialized equipment that allows us to take out the bone marrow, and we also have the amnion product that “hops up” the bone marrow. In Panama, we have a 16,000 square foot laboratory where we isolate the stem cells from umbilical cells, grow them out, freeze them down, and then we thaw them as required for use. All the hard work in Panama is in the laboratory because the actual therapy is nothing more, as you know.

Larry: Now, are there a lot of labs in the world that produce those types of cells?

NR: There’s about a handful. We’re creating a wedge with this Duchenne’s, and we’re creating a wedge for larger studies with more individuals.

Larry: Our callers touched upon it a little bit with pharma, I imagine there’s a lot of red tape and lobbying and I imagine pharma’s a lot of the pushback on why you’re not able to have your labs all over the United States.

NR: If you take rheumatoid arthritis as an example, and there was a study that came out where they treated over 172 people with umbilical MSCs, and all of them improved, after one infusion.

Larry: This is huge for those patients, because it’s very painful and there’s no cure before stem cells.

NR: If you look at the drugs that you hear about all the time watching television, you see these anti-rheumatic drugs over and over again, and they represent a 14 billion dollar industry in the US. So if you have a competitor that’s not yet FDA approved, there’s not going to be a great deal of pharma support for that.

Larry: Am I wrong in believe that the future is here, stem cells are going to be much bigger in peoples’ lives than they ever imagined?

NR: Yeah, I think it’s definitely right up there with vaccinations and antibiotics as far as the next leap forward in medicine, and as congressman Joe Barton pointed out in a meeting we had a couple of months ago, the truth always comes out. Sometimes it takes longer, and in this case the effectiveness of these cells, the safety of these cells, the naturalness of these cells, all those truths will become self evident at some point. How long it takes, I don’t know. There are other countries investing and building a regulatory process that will speed things up. For example, Japan has put in rules and regulations that will speed things up. Germany, South Korea, and Taiwan are right behind Japan. They’re going to allow for innovation like we’ve never seen before. If we don’t do something in this country, we’re going to be left in the dust. So, Japan’s rule basically states that once you prove the safety of your product, it can go to market for seven years, and in that seven years you can demonstrate what it’s effective for. I think we need something like that in this country if we’re going to stay competitive. There’s a bill being revised right now called the Renew Act. I don’t know that that’s going to make it, but we need something like it or for one of the states to create a statute much like medical marijuana, where the state of Colorado has said in spite of federal regulations we’re going to allow this and the attorney general’s going to back us up. I think Texas has a pretty good chance of that. I just got back from Kansas, and they’ve got a pretty good chance too.

Larry: Partly because of you! You’re at the forefront pushing and lobbying and really trying to create awareness.

NR: If you look at the economic benefit, I hate to use marijuana as a comparative, but if you look at the economics in Colorado, the state coffers are swollen with cash, and I think that would happen if a state were to say to the federal government, this is what we’re going to do. There’s enough evidence of safety, certainly with the patient’s own stem cells, with the post-natal stem cells, there’s enough safety data that one state will stand up, or the federal government’s going to have to make a break.

Larry: Any parting words?

NR: I think the best resource is www.cellmedicine.com and RMIclinic.com. It tells you everything we do and don’t do.

Dr. McKenna of Riordan-McKenna Institute teaches at an orthopedic surgery conference in Milan, Italy.

From Facebook: Busy week that ended with me doing surgery teaching at the Largest shoulder course in Europe. The Spalla Shoulder course in Milan Italy . My talk and surgery demonstration video was the first scheduled lecture after lunch. 2 PM Italian time which meant 7am Texas time!!! This was the first surgical demonstration of the Hemicap partial shoulder replacement technique that I just got published in Decembers journal of shoulder and elbow surgery.

The first picture is me In front of the cameras and my computer giving the lecture in Milan live from my kitchen table. The second picture is from the lecture hall in Milan from the crowds perspective. Thank you Mike Mitchell and Shannon for setting this up where I could still give my talk and not have to leave the country at such a crucial time for RMI…Live surgery Demonstration broadcast to the Spalla shoulder and elbow course in Milan Italy. Thanks to Dr Castagna for the invitation and opportunity to share our new technique with orthopedic surgeons from all over the world.

Dr. R Wade Mckenna addresses a medical conference in Milan, Italy. Dr. McKenna is partners with Dr. Riordan at the Riordan-McKenna Institute of Regenerative Medicine for Orthopedics in Southlake, Texas.

Posted by The Stem Cell Institute on Monday, February 15, 2016

2016-02-15T19:50:05+00:00 February 15th, 2016|Dr. Wade McKenna, News, Riordan-McKenna Institute, Shoulder Surgery|

Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy

IV-Vitamin-CNina Mikirova, Neil Riordan, Joseph Casciari

Med Sci Monit 2016; 22:14-25
DOI: 10.12659/MSM.895368

BACKGROUND: Cytokines play an important role in tumor angiogenesis and inflammation. There is evidence in the literature that high doses of ascorbate can reduce inflammatory cytokine levels in cancer patients. The objective of this study was to investigate the effect of treatment by intravenous vitamin C (IVC) on cytokines and tumor markers.

MATERIAL AND METHODS: With the availability of protein array kits allowing assessment of many cytokines in a single sample, we measured 174 cytokines and additional 54 proteins and tumor markers in 12 cancer patients before and after a series of IVC treatments.

RESULTS: Presented results show for our 12 patients the effect of treatment resulted in normalization of many cytokine levels. Cytokines that were most consistently elevated prior to treatments included M-CSF-R, Leptin, EGF, FGF-6, TNF-α, β, TARC, MCP-1,4, MIP, IL-4, 10, IL-4, and TGF-β. Cytokine levels tended to decrease during the course of treatment. These include mitogens (EGF, Fit-3 ligand, HGF, IGF-1, IL-21R) and chemo-attractants (CTAC, Eotaxin, E-selectin, Lymphotactin, MIP-1, MCP-1, TARC, SDF-1), as well as inflammation and angiogenesis factors (FGF-6, IL-1β, TGF-1).

CONCLUSIONS: We are able to show that average z-scores for several inflammatory and angiogenesis promoting cytokines are positive, indicating that they are higher than averages for healthy controls, and that their levels decreased over the course of treatment. In addition, serum concentrations of tumor markers decreased during the time period of IVC treatment and there were reductions in cMyc and Ras, 2 proteins implicated in being upregulated in cancer.

Read Full Article…

2016-02-15T17:06:37+00:00 February 15th, 2016|Cancer, Neil Riordan, News, PhD|

Stem Cell Therapy: Study finds that autologous bone marrow disc injections significantly reduce lumbar disc pain

A study published last year (2015) in the scientific journal Stem Cells entitled “Percutaneous injection of autologous bone marrow concentrate significantly reduces lumbar discogenic pain through 12 months”, reported that patients suffering from chronic back pain due to degenerative disc disease who were treated by injecting their own bone marrow aspirate concentrate (BMAC) into their lumbar discs experienced significant pain reduction 12 months after treatment.

Woman Back PainDegenerative disc disease (DDD) is a term used to describe normal changes in spinal discs as one ages. Spinal discs separate the spinal vertebrae and act as shock absorbers that allow the spine to twist, bend and flex. DDD usually affects the discs in the lower back (lumbar) or the neck (cervical).

DDD in lumbar discs can cause lower back pain, osteoarthritis, abnormal disc bulging (herniated disc) and spinal stenosis (narrowing of the tunnel-like space that holds the spinal cord), any of which can exert pressure on spinal nerves and the spinal cord causing pain and affecting nerve function.

BMAC contains mesenchymal stem cells and CD34+ stem cells. Mesenchymal stem cells have been shown to promote tissue growth including cartilage and CD34+ stem cells can promote tissue vascularization, thus increasing blood supply to new or damaged tissue.

The researchers studied 26 patients who were suffering from discogenic lower back pain. Patients were followed up at 3, 6, and 12 months.

After 12 months, 21 out of 26 patients experienced statistically significant improvements in pain scores and impairment. The most dramatic improvements were seen in patients with higher stem cell counts.

The original publication can be found here: http://onlinelibrary.wiley.com/doi/10.1002/stem.1845/epdf

At Riordan-McKenna Institute, Dr. Riordan’s orthopedic stem cell clinic in Dallas-Fort Worth, Dr. McKenna performs a procedure for degenerative disc disease that is similar to the one described in the Stem Cell Journal study.

However, Dr. McKenna augments the BMAC injections with *AlphaGEMS amniotic tissue product. AlphaGEMS is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of AlphaGEMS adds a new dimension to the tissue repair process that was successfully tested in the cited study.

“Since we perform lumbar disc injections with BMAC and AphaGEMS at RMI, we are encouraged to see an independent study published that shows the effectiveness of a similar procedure for patients suffering from discogenic lumbar back pain,” states Riordan-McKenna Institute Medical Director, Wade McKenna, DO.

For more information about BMAC and AlphaGEMS treatment at RMI, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

If you are suffering from degenerative disc disease and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once we receive it, our staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.

https://secureform.rmiclinic.com/forms/13299/3207/VVp7/form.html


*AlphaGEMS tissue is procured from contracted hospitals after normal, healthy births

Stem Cell-Augmented Achilles Tendon Rupture Repair Yields Excellent Results

Int Orthop. 2015 May;39(5):901-5. doi: 10.1007/s00264-015-2725-7. Epub 2015 Mar 22.

Outcomes of acute Achilles tendon rupture repair with bone marrow aspirate concentrate (BMAC) augmentation

Stein BE, Stroh DA, Schon LC.

“Excellent results, including no re-ruptures and early mobilisation, were observed…”

Abstract

Kobe-AchillesPURPOSE:
Optimal treatment of acute Achilles tendon ruptures remains controversial. Positive results using stem-cell-bearing concentrates have been reported with other soft-tissue repairs, but no studies exist on outcomes of bone marrow aspirate concentrate (BMAC) augmentation in primary Achilles tendon repair.

METHODS:
We reviewed patients with sport-related Achilles tendon ruptures treated via open repair augmented with BMAC injection from 2009 to 2011. Data on operative complications, strength, range of motion, rerupture, calf circumference and functional improvement through progressive return to sport and the Achilles tendon Total Rupture Score (ATRS) were analysed.

RESULTS:
A total of 27 patients (28 tendons) treated with open repair and BMAC injection were identified (mean age 38.3 ± 9.6 years). At mean follow-up of 29.7 ± 6.1 months, there were no reruptures. Walking without a boot was at 1.8 ± 0.7 months, participation in light activity was at 3.4 ± 1.8 months and 92% (25 of 27) of patients returned to their sport at 5.9 ± 1.8 months. Mean ATRS at final follow-up was 91 (range 72-100) points. One case of superficial wound dehiscence healed with local wound care. No soft-tissue masses, bone formation or tumors were observed in the operative extremity.

CONCLUSIONS:
Excellent results, including no re-ruptures and early mobilisation, were observed in this small cohort with open Achilles tendon repair augmented by BMAC. No adverse outcomes of biologic treatment were observed with this protocol. The efficacy of BMAC in the operative repair of acute Achilles tendon ruptures warrants further study.

LEVEL OF EVIDENCE:
IV – Therapeutic.

Ruptured Achilles Tendon Treatment at Dr. Riordan’s Clinic in Dallas-Fort Worth

At Riordan-McKenna Institute, Dr. McKenna performs a procedure for achilles tendon rupture that is similar to the one described in this study. However, Dr. McKenna augments the BMAC injection with AlphaGEMS amniotic tissue product. AlphaGEMS is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of AlphaGEMS adds a new dimension to the tissue repair process.

For more information about BMAC and AlphaGEMS treatment at RMI, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

If you have suffered a ruptured achilles tendon and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once we receive it, our staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.

https://secureform.rmiclinic.com/forms/13299/3207/VVp7/form.html

Recent Study Concludes Patients’ Own Stem Cells with Core Decompression Could Delay or Avoid the Need for Hip Replacement

A recent University of Rome study published in Acta Orhopaedica Belgica entitled “Stage-Related Results In Treatment Of Hip Osteonecrosis With Core-Decompression And Autologous Mesenchymal Stem Cells” reported that avascular hip necrosis patients treated with a combination of bone marrow aspirate concentrate (BMAC) and surgical core decompression experienced significant improvements that could delay or avoid the need for hip replacement.

Femoral Head RoundedOsteonecrosis is the death of bone tissue caused by lack of blood supply to the bone. Another name for osteonecrosis is avascular necrosis. Tiny breaks in the bone caused by avascular necrosis can eventually lead to bone collapse. If the bone is fractures or becomes dislocated, its blood supply can be cut off. Early stage avascular necrosis may be treated with a combination of physical therapy, however most people with avascular necrosis will eventually need surgery including total joint replacement.

Core decompression is surgical procedure that involves removing part of the inside of the bone to relieve pressure and allow new blood vessels to form.

BMAC contains mesenchymal stem cells and CD34+ stem cells. Mesenchymal stem cells have been shown to promote tissue growth including cartilage and CD34+ stem cells can promote tissue vascularization, thus increasing blood supply to new or damaged tissue.

The researchers studied 29 patients (31 total hips) with Stage I and Stage II avascular osteonecrosis of the femoral head (AVNFH). The femoral head is the “ball” end of the thigh bone that fits into the hip socket. Patients were followed-up for two years after their procedures.

After 2 years, 25 out of 31 hips showed a relief of symptoms and a resolution of the osteonecrosis. The researchers concluded, “…treatment of AVNFH with implantation of autologous concentrated MSCs is indicated for patients at Stage I and Stage II”. They went on to state, “Our results show a significant reduction of joint pain level, and this could take to a delay, or avoid the need, of hip replacement.” Another significant finding was the association of corticosteroid therapy to a larger chance of treatment failure.

The original publication can be found here: http://www.actaorthopaedica.be/acta/download/2015-3/09-Persiani%20et%20al.pdf

At Riordan-McKenna Institute, Dr. McKenna performs a procedure for AVFNH that is similar to the one described in the Italian study. However, Dr. McKenna augments the BMAC injection with AlphaGEMS amniotic tissue product. AlphaGEMS is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of AlphaGEMS adds a new dimension to the tissue repair process that was successfully tested in Rome.

“Since we perform core decompression with stem cell therapy at RMI, we are encouraged to see independent study results published that show the effectiveness of a similar procedure for patients with avascular necrosis of the femoral head,” states Riordan-McKenna Institute Medical Director, Wade McKenna, DO.

For more information about BMAC and AlphaGEMS treatment at RMI, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

If you are suffering from avascular osteonecrosis of the femoral head and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once they receive it, RMI staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.

https://secureform.rmiclinic.com/forms/13299/3207/VVp7/form.html

Study Shows Bone Marrow Stem Cells Help Tennis Elbow

Tennis Elbow

A study published in the Jul-Dec 2014 edition of the Journal of Natural Science, Biology and Medicine entitled Bone marrow injection: A novel treatment for tennis elbow concludes that a single injection of bone marrow aspirate concentrate (BMAC) into the elbow lead to significant improvement of patients suffering from tennis elbow.

The study followed 30 patients for 12 weeks and concluded that treatment of tennis elbow patients with single injection of BMA showed a significant improvement in short to medium term follow-up.

Perhaps more importantly, it concluded that, “In future, such growth factors and/or stem cells based injection therapy can be developed as an alternative conservative treatment for patients of tennis elbow, especially who have failed non-operative treatment before surgical intervention is taken.”

Fast forward to the present where at RMI, we are augmenting BMAC with *AlphaGEMS, a proprietary, pliable tissue allograft (transplant) derived from human placental amnion, which functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. AlphaGEMS contains 108 different growth factors including WNT-4 and prostaglandin.

Prostaglandin inhibits inflammation, which occurs after injury and marks the beginning of the healing process. The faster we can tame this inflammation, the sooner the body can move on to the next phase of healing, regeneration. It’s important to note that AlphaGEMS has more than 60 times the amount of prostaglandin compared to other products.

WNT4 is arguably the single most important molecule required for wound healing. AlphaGEMS has more than 10 times the amount of WNT4 as competing products.

For more information about BMAC and AlphaGEMS at the Riordan-McKenna Institute Click Here.

If you are suffering from tennis elbow and would like to be evaluated for treatment, please start by completing our online medical history. Once we receive it, our staff will contact you to answer general questions and guide you through the rest of the application process, which usually includes a in-office evaluation with Dr. McKenna for local patients or a free telephone consultation for those who live further away.

Apply Today

About Tennis Elbow

Tennis elbow is an inflammation of the tendons that join the forearm muscles on the outside of the elbow. The forearm muscles and tendons become damaged from overuse — repeating the same motions again and again. This leads to pain and tenderness on the outside of the elbow. More on Tennis Elbow from AAOS.

About: Bone marrow injection: A novel treatment for tennis elbow

Abstract

Objective:

The objective of this prospective study was assessment of efficacy of bone marrow aspirate (BMA) (containing plasma rich in growth factors and mesenchymal stem cells) injection in treatment of tennis elbow.

Materials and Methods:

A total of 30 adult patients of previously untreated tennis elbow were administered single injection of BMA. This concentrate was made by centrifugation of iliac BMA at 2000 rpm for 20-30 min and only upper layer containing platelet rich plasma and mononuclear cells was injected. Assessment was performed at baseline, 2 weeks, 6 weeks and 12 weeks using Patient-rated Tennis Elbow Evaluation (PRTEE) score.

Results:

Baseline pre-injection mean PRTEE score was 72.8 ± 6.97 which decreased to a mean PRTEE score of 40.93 ± 5.94 after 2 weeks of injection which was highly significant (P < 0.0001). The mean PRTEE score at 6 week and 12 week follow-up was 24.46 ± 4.58 and 14.86 ± 3.48 respectively showing a highly significant decrease from baseline scores (P < 0.0001). Conclusion:

Treatment of tennis elbow patients with single injection of BMA showed a significant improvement in short to medium term follow-up. In future, such growth factors and/or stem cells based injection therapy can be developed as an alternative conservative treatment for patients of tennis elbow, especially who have failed non-operative treatment before surgical intervention is taken.




*Tissue used for AlphaGEMS is donated after normal, healthy births. Once it has been fully tested for infectious diseases, sterility and a few other things, the tissue is processed by using proprietary methods developed by Neil Riordan, PhD.

PRESS RELEASE – UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute

MRI confirms complete healing of hamstring eight weeks after Dr. Wade McKenna administered guided injections of bone marrow aspirate concentrate (BMAC) harvested with BioMAC (patent pending) bone marrow aspiration cannula and AlphGEMS amniotic tissue product at the Riordan-McKenna Institute.

DALLAS-FORT WORTH, TEXAS (PRWEB) SEPTEMBER 03, 2015

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

UCLA wide receiver and Canadian decathlon standout, Zack Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zack decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the BioMAC (patent pending) bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

http://www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496